Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denifanstat in Non-Alcoholic Steatohepatitis (FASCINATE-1)
NCT03938246Phase 2Completed
- Sponsor
- Sagimet Biosciences
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of denifanstat in metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Sagimet Biosciences. Primary endpoint: Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at 12 weeks. Started Mar 2019; status: completed.
02
Drugs
denifanstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT03938246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938246.